StockpollyBeta
Get App
Popularity #2,092
CRBP · NASDAQ · Biotechnology

Corbus Pharmaceuticals (CRBP)

Develops CRB-701 for oncology and CRB-913 for obesity.

$7.74
After hours−0.01 (−0.19%)
At close$7.76(−1.52%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue0000001600000
Gross profit000000−1600000
9101011161241924222436
Research & development7767119161521182031
334454444445
Selling & marketing000000000000
General & administrative304450444445
Other expenses000000−1600000
Operating income−9−10−10−11−16−13−20−19−24−22−24−36
−123123311111
Interest income000114211110
Interest expense110100000000
Other non-operating income0−3−4−2−2−3−1−1−1−1−1−1
Income before tax−10−8−7−10−14−10−17−18−23−21−23−35
Net income from continuing operations−10−8−7−10−14−10−17−18−23−21−23−35
Net income−10−8−7−10−14−10−17−18−23−21−23−35
EPS, basic−$2.27−$1.81−$2.45−$3.55−$1.15−$0.78−$1.39−$1.44−$1.90−$1.54−$1.23−$1.81
EPS, diluted−$2.27−$1.81−$2.45−$3.55−$1.15−$0.78−$1.39−$1.44−$1.90−$1.54−$1.23−$1.81
Weighted average shares, basic44331212121212131919
Weighted average shares, diluted44331212121212131919
EBITDA−9−7−6−9−13−9−19−18−23−21−23−34
Depreciation & amortization000000000001
EBIT−9−7−6−9−13−10−19−18−23−21−23−35